Huang B J, Huang T J, Liang Q W, Huang C W, Fang Y
Department of Etiology, Cancer Institute, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China.
Yi Chuan Xue Bao. 2001;28(9):793-800.
To investigate the frequency of HER-2 oncogene amplification in primary hepatocellular carcinoma (HCCs) and its relationships with clinicopathological parameters and prognosis, 42 surgical samples from patients with primary HCCs were detected for their HER-2 oncogene amplification by dual FISH technique, and then the correlations between HER-2 amplification and clinicopathological characteristics and prognosis were analyzed statistically. HER-2 oncogene amplification was detected in 9 of 42 (21.4%) primary HCCs, including 4 (9.5%) cases with high copy (HC) and 5 (11.9%) ones with low copy (LC). HER-2 amplification was associated significantly with postoperative survival time of HCC patients examined (P = 0.046) and the presence of HER-2 gene amplification showed a trend toward a correlation with tumor size (P = 0.085), but wasn't relative to sex, age, AFP level, HBV infection, postoperative relapse and clinical staging of HCC patients tested (P > 0.05). On the other hand, gain of the HER-2 oncogene copy was examined in 31 of 42(73.8%) primary HCCs, consisting of 9 (21.4%) cases with HER-2 amplification and 22(52.4%) ones with aneusomy 17/polysomy 17. There weren't significant relationships between gain of HER-2 oncogene copy and, HCC patient's sex, tumor size, clinical staging, postoperative relapse and survival time (P > 0.05), but gain of HER-2 oncogene copy correlated significantly to patients' age, AFP level and HBV infection (P < 0.05). The study indicated that there were a lower frequency of HER-2 oncogene amplification and a higher frequency of aneusomy 17/polysomy 17 in primary HCCs and that HER-2 oncogene amplification activation might be involved in the development and progression of a subset of HCCs, and seemed to be a valuably independent prognosis factor predicting postoperative poorer survival for patients with HCC.
为研究原发性肝细胞癌（HCC）中HER-2癌基因扩增的频率及其与临床病理参数和预后的关系，采用双色荧光原位杂交（FISH）技术检测42例原发性HCC患者手术标本的HER-2癌基因扩增情况，并对HER-2扩增与临床病理特征及预后的相关性进行统计学分析。42例原发性HCC中9例（21.4%）检测到HER-2癌基因扩增，其中高拷贝（HC）4例（9.5%），低拷贝（LC）5例（11.9%）。HER-2扩增与HCC患者术后生存时间显著相关（P = 0.046），HER-2基因扩增的存在与肿瘤大小呈相关趋势（P = 0.085），但与检测的HCC患者的性别、年龄、甲胎蛋白（AFP）水平、乙肝病毒（HBV）感染、术后复发及临床分期无关（P > 0.05）。另一方面，42例原发性HCC中31例（73.8%）检测到HER-2癌基因拷贝数增加，其中HER-2扩增9例（21.4%），17号染色体非整倍体/多倍体22例（52.4%）。HER-2癌基因拷贝数增加与HCC患者的性别、肿瘤大小、临床分期、术后复发及生存时间无显著相关性（P > 0.05），但与患者年龄、AFP水平及HBV感染显著相关（P < 0.05）。研究表明，原发性HCC中HER-2癌基因扩增频率较低，17号染色体非整倍体/多倍体频率较高，HER-2癌基因扩增激活可能参与了一部分HCC的发生发展，似乎是预测HCC患者术后生存较差的有价值的独立预后因素。
